Connect your AI

Pulmonx Corporation LUNG Issuance of common stock warrants

Other financials

Income statement

Revenue$20.6M-8.7%

Gross profit$16.0M-1.8%

Operating income-$13.0M+11.0%

Net income-$13.7M+5.5%

EPS (diluted)-$0.33+8.3%

Balance sheet

Cash & equivalents$61.0M-2.4%

Total debt$56.3M-1.2%

Total equity$45.8M-41.1%

Total assets$120.0M-20.4%

Cash flow

Operating cash flow-$10.1M+23.6%

CapEx$9.0K-97.0%

Free cash flow-$10.1M+25.3%

Valuation

Market cap$54.91M-43.7%

Enterprise value$50.17M-39.2%

P/S0.6×-0.5×

Profitability

Gross margin75.5%+2.0pp

Operating margin-58.8%-5.8pp

Net margin-60.1%-4.4pp

FCF margin-33.2%-4.4pp

Returns & leverage

Return on equity-86.2%+62.6pp

Debt / equity1.2×+0.5×

Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept lung:WarrantsIssued.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's issuance of common stock warrants.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pulmonx Corporation's issuance of common stock warrants?: Pulmonx Corporation (LUNG) reported issuance of common stock warrants of $1.38M in Q1 2026.